Can flow cytometry detect successful ticlopidine treatment in patients with VVI pacemakers?
An increased platelet activation status is present in patients with VVI pacemakers. With platelet activation, there is modulation of platelet surface molecule expression. In the current study, the expression of platelet surface markers in VVI patients before and after ticlopidine treatment and control subjects was investigated by means of flow cytometry. The study group consisted of 25 patients with VVI pacemaker, and 15 control subjects. CD42b, CD61, and CD62p expression were significantly increased in VVI patients compared with control subjects (CD42b p < 0.001, CD61 p< 0.005 and CD62p p < 0.001). In addition, after ticlopidine treatment, platelets showed a significant fall in expression of all these markers in VVI patients (CD42b p < 0.001, CD61 p < 0.005 and CD62p p< 0.001). Our data suggest an increase of the surface expression of all these markers on platelets and demonstrate the efficacy of ticlopidine in reducing them.
Koşar
F
F
Department of Cardiology, Ankara Yüksek Ihtisas Hospital, Gaziler Sok No. 18/9, 06610 Abidinpaşa, Ankara, Turkey.
Durmaz
T
T
Hisar
I
I
Ayaz
S
S
Saşmaz
H
H
Korkmaz
S
S
Saşmaz
A
A
D015415:Biomarkers / Q000097:blood; D001792:Blood Platelets / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry / Q000592:standards*; D006327:Heart Block / Q000097:blood* / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial / Q000009:adverse effects*; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013988:Ticlopidine / Q000627:therapeutic use*; D016896:Treatment Outcome
D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine